NCT07190261View on ClinicalTrials.gov

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

September 18, 2027

Study Completion Date

September 18, 2027

Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG

enatumab

The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.

Trial Locations (1)

100730

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Bing Han

OTHER